Justin Green

Justin is a UK-accredited Infectious Diseases physician with a PhD in tuberculosis immunology from Imperial College London. He completed his medical training at Cambridge and Oxford before transitioning into global health roles in the pharmaceutical sector.

At GSK Global Health, Justin worked on neglected tropical diseases, including leishmaniasis and malaria. He led pivotal Phase 3 clinical trials that resulted in the FDA and TGA approvals of tafenoquine, the first new <em>Plasmodium vivax</em> anti-relapse treatment in over 60 years. He also played an instrumental role in developing a novel paediatric formulation.

In 2018, Justin joined ViiV Healthcare to lead its paediatric HIV portfolio. As Medicines Development Leader, he was responsible for a key regulatory submission that gained FDA approval for a dispersible version of dolutegravir, one of WHO’s most important paediatric antiretrovirals.

At the height of the COVID-19 pandemic, he moved to AstraZeneca to work on the not-for-profit COVID-19 vaccine, Vaxzevria. As Global Project Lead, he oversaw the vaccine’s authorisation in over 100 countries and its global management until its retirement in 2024.

Justin is now focused on advancing global child health through the development of new antibiotics and paediatric formulations. His work spans strategy, clinical development, and collaborative partnerships aimed at expanding access to essential medicines in underserved populations.

Outside of his professional life, Justin enjoys spending time on his allotment, coaching his son’s rugby team, running, and supporting Brentford FC in the English Premier League.